SML0422
伊司茶碱
≥98% (HPLC)
别名:
(E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine, 8-[(1E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, KW-6002
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H24N4O4
化学文摘社编号:
分子量:
384.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+
SMILES string
CCN1C(=O)N(CC)c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2C1=O
InChI key
IQVRBWUUXZMOPW-PKNBQFBNSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL (clear solution)
storage temp.
2-8°C
Quality Level
Gene Information
human ... ADORA2A(135)
Biochem/physiol Actions
Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist which has been investigated for use in Parkinson′s Disease.
Istradefylline (KW-6002) is a potent and selective adenosine A2A receptor selective antagonist.
Features and Benefits
This compound is featured on the Adenosine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Peter Jenner
Expert opinion on investigational drugs, 14(6), 729-738 (2005-07-12)
Dopamine replacement therapy effectively treats the early motor symptoms of Parkinson's disease (PD). However, its association with the development of motor complications limits its usefulness in late stages of the disease. Adenosine A(2A) receptors are localised to the indirect striatal
Nikoletta Szabó et al.
Expert opinion on drug metabolism & toxicology, 7(4), 441-455 (2011-02-22)
Parkinson's disease (PD) is a progressive neurodegenerative disorder. To date, most of the currently available therapies in PD target the dopaminergic system and none of these therapeutic approaches have been proven to modify the course of the disease. To various
P Jenner et al.
Parkinsonism & related disorders, 15(6), 406-413 (2009-05-19)
Adenosine derived from the degradation of ATP/AMP functions as a signalling molecule in the nervous system through the occupation of A1, A2, and A3 adenosine receptors. Adenosine A(2A) receptors have a selective localization to the basal ganglia and specifically to
Robert A Hauser et al.
Movement disorders : official journal of the Movement Disorder Society, 23(15), 2177-2185 (2008-10-04)
The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW-6002) is an
John D Salamone et al.
Behavioural brain research, 201(1), 216-222 (2009-05-12)
Adenosine and dopamine receptors in striatal areas interact to regulate a number of different functions, including aspects of motor control and motivation. Recent studies indicate that adenosine A(2A) receptor antagonists can reverse the effects of dopamine (DA) D(2) antagonists on
商品
We offers many products related to adenosine receptors for your research needs.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持